Turnstone Biologics

Turnstone Biologics is a clinical-stage biotechnology company dedicated to developing new medicines to treat and cure patients with solid tumors. Their approach focuses on pioneering "Selected TIL" therapy, a differentiated approach to tumor infiltrating lymphocytes (TILs). Unlike conventional "bulk TIL" methods, Turnstone's process identifies, selects, and expands the most potent tumor-reactive T cells, aiming to overcome limitations of first-generation TIL therapies. This strategy is designed for broader application across a range of solid tumors, potentially delivering transformative therapies for patients underserved by current options.

Turnstone's lead program, TIDAL-01, is currently being evaluated in multiple Phase 1 studies in patients with colorectal cancer, head and neck cancer, and uveal melanoma. Their pipeline also includes TIDAL-02, a next-generation Selected TIL program, and a combination program of TIDAL-01 and viral immunotherapy. Turnstone boasts an experienced management team, a distinguished Scientific Advisory Board, and strategic partnerships with key academic institutions, major biopharmaceutical companies, and international cancer medical centers.

Turnstone Biologics is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. They are pioneering a differentiated approach to tumor infiltrating lymphocytes (TILs) by selecting the most potent and tumor-reactive T cells, known as Selected TILs, to overcome the limitations of first-generation bulk TIL therapies. Their mission is to shift the paradigm for the treatment of solid tumors by creating curative immunotherapies that target a broader range of cancer types, including those that have historically been resistant to treatment.

Turnstone Biologics promotes a culture of innovation, execution, and excellence. They emphasize a sense of urgency in fulfilling their mission to cure solid tumors, driven by bold science and a patient-centric approach. The company is committed to fostering a values-driven environment that embraces diversity and equity, recognizing the power of collective effort in achieving success.

Turnstone Biologics is committed to building a values-driven organization that embraces diversity, equity, and inclusion, recognizing that the sum of its parts drives more success than any single individual. The company believes that its talented people and deeply ingrained culture are vital elements in maintaining its competitive edge in the vast biotech universe and key to unlocking the full potential of cancer immunotherapy.